|
WO2019140102A1
|
|
Compositions and methods for facilitating delivery of synthetic nucleic acids to cells
|
|
WO2019040590A1
|
|
Modulation of soluble fas expression
|
|
US2018298384A1
|
|
Compositions and methods for modulating SMN gene family expression
|
|
WO2018031871A1
|
|
Ex vivo modulation of foxp3 expression
|
|
CA3030701A1
|
|
Nucleic acid conjugates and uses thereof
|
|
WO2017181026A1
|
|
Selective modulation of foxp3 expression
|
|
CA3003267A1
|
|
Nanoparticle formulations for delivery of nucleic acid complexes
|
|
US2019055553A1
|
|
Methods for identifying and targeting non-coding rna scaffolds
|
|
US2018030452A1
|
|
Targeting oligonucleotides and uses thereof to modulate gene expression
|
|
AU2016219052A1
|
|
Compositions and methods for modulating RNA
|
|
US2018028557A1
|
|
Hybrid oligonucleotides and uses thereof
|
|
US2016222391A1
|
|
Compositions and methods for treating amyotrophic lateral sclerosis
|
|
AU2014306416A1
|
|
Compositions and methods for modulating RNA
|
|
AU2013315225A1
|
|
Multimeric oligonucleotide compounds
|
|
US2015159160A1
|
|
Compositions and methods for modulating ATP2A2 expression
|
|
AU2012308320A1
|
|
Multimeric oligonucleotide compounds
|
